Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002827 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
A Phase 3 study of Lymphoma and Cardiac Toxicity, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 294
- Enrollment target
- 20
- Study locations
NCT00002827 is a Phase 3 study of Lymphoma and Cardiac Toxicity that has completed, run by Children's Oncology Group. The registered enrollment target is 294 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00002827, a Phase 3 study of Lymphoma and Cardiac Toxicity, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 294 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is more effective with or without dexrazoxane for Hodgkin's disease. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II, or stage III Hodgkin's disease.
Conditions Studied
Interventions
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG dexrazoxane hydrochloride
- DRUG doxorubicin hydrochloride
- BIOLOGICAL bleomycin sulfate
Study Locations (20)
California
- Long Beach Memorial Medical Center - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Cancer Center and Cancer Research Institute - San Francisco
- David Grant Medical Center - Travis Air Force Base
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- CCOP - Kalamazoo - Kalamazoo
Minnesota
- University of Minnesota Cancer Center - Minneapolis
- Mayo Clinic Cancer Center - Rochester
New York
- Kaplan Cancer Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Colorado
- Children's Hospital of Denver - Denver
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 1996-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002827
The ClinicalTrials.gov registry entry for NCT00002827 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (39% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which etoposide is the first listed.
NCT00002827 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00002827 about?
NCT00002827 is a clinical study titled "Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. It is not yet known if chemotherapy is ...
What is the current status of trial NCT00002827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 1996-10. Estimated completion is 2008-06.
What conditions does trial NCT00002827 study?
This clinical trial studies the following conditions: Lymphoma, Cardiac Toxicity.
What interventions are being tested in trial NCT00002827?
The interventions under investigation include: etoposide (DRUG), filgrastim (BIOLOGICAL), dexrazoxane hydrochloride (DRUG), doxorubicin hydrochloride (DRUG), bleomycin sulfate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002827?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002827 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.